<DOC>
	<DOCNO>NCT00700895</DOCNO>
	<brief_summary>Interethnic difference warfarin dose requirement Asian population well describe . Our previous study show warfarin maintenance dose multi-ethnic population closely related patient demographic genetic polymorphism cytochrome ( CYP ) P4502C9 vitamin K epoxide reductase complex subunit 1 ( VKORC1 ) . A retrospective regression model combine predictor account 57.8 % variability warfarin dose .</brief_summary>
	<brief_title>Assessing Clinical Benefits Pharmacogenetics-Guided Dosing Regiment Calculating Warfarin Maintenance Dose</brief_title>
	<detailed_description>Hypothesis : We hypothesize warfarin dose requirement could accurately predict use simplified genotyping procedure require identification single CYP2C9 allele single nucleotide polymorphism VKORC1 discern 2 major haplotype H1 H7 . Aims : The aim compare clinical benefit genetics-guided dose versus traditional trial error dose protocol guided-adjustments . Two secondary objective ( 1 ) prospectively evaluate dosing algorithm build demographic genetic predictor ; ( 2 ) ass feasibility simplify test CYP2C9*3 VKORC1 SNP clinical practice . Methodology : A randomized control trial target accrue 100 patient indication wafarin therapy . The endpoint compare genetics-guided dose traditional dosing method anticoagulant clinic number dosage titration achieve target International Normalized Ratio ( INR ) 1 , 2 3 month initialize warfarin . Upon reach steady-state , pharmacokinetics warfarin R- S-isomers assessed correlation dose requirement base . An assay easy identification genetic polymorphism require dose regimen clinic setting also validate . Significance : This concerted , multi-disciplinary effort bring pharmacogenetics-based therapy bench bedside potential reduce effort incur multiple dose titration commonly prescribe oral anticoagulant . With aid mathematical modeling , simplify cost-effective genotyping method could implementation future treatment prophylaxis thromboembolic disease .</detailed_description>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . At least 18 year age 2 . New indication warfarin therapy 3 . No previous history liver disease ; transaminases must less 3 time upper limit normal bilirubin within normal range 4 . No previous history malabsorption syndrome chronic diarrheal condition 5 . Written , inform consent 1 . Uncontrolled hypertension 2 . Peptic ulcer disease 3 . Any medical condition deem unfit warfarin therapy base clinical judgement primary physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>